This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Aplastic and Other Anemias > Efficacy > Aplastic Anemia
Print

In this section:

Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC
Aplastic Anemia

EXJADE Delivers Significant Efficacy in Treating Iron Toxicity for Patients With Aplastic Anemia

EXJADE reduces serum ferritin levels


In 2010, the 1-year EPIC study showed that EXJADE effectively reduced serum ferritin levels in patients with aplastic anemia (n=116).1

APLASTIC ANEMIA1
-964
μg/L at 1 year P=.0003 (n=116)
based on
LOCF
 analysis

Serum Ferritin Reduced Over 1 Year by EXJADE1

Serum Ferritin Reductions in Aplastic Anemia1
Serum ferritin reduction with EXJADE
Patients experienced dose-dependent reduction1
Significant reduction (P<.0001) in serum ferritin levels2

TAILORED CHELATION
THERAPY

Meet your patients’
needs with EXJADE.

Learn more

DIFFERENCES BETWEEN
APLASTIC AND
OTHER ANEMIAS

A variety of rare
anemias exist, each
with their own specific
characteristics.

Learn more

EXJADE has shown efficacy in reducing liver iron concentration levels

In 2007, a 1-year study in patients across a range of anemias (N=184) showed that EXJADE reduced liver iron concentration in with rare anemia patients, including aplastic anemia.3

EXJADE Reduces Liver Iron Concentration in Patients
With Rare Anemias (including aplastic anemia)2
EXJADE Efficacy in Reducing Liver Iron Concentration Levels
More Information
Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC

References

  1. Lee JW, Yoon SS, Shen ZX, Ganser A, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-2454.
  2. Data on file. Novartis Pharma AG, Basel, Switzerland.
  3. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed
Mean Liver Iron Concentration Reduction from Baseline Chart Iron Concentration Reduction for Patients with other Rare Anemias Mean Liver Iron Concentration Reduction from Baseline Chart Iron Concentration Reduction for Patients with other Rare Anemias